Product Description
BIIB061 is an oral small molecule that induces growth of the cells that make myelin potentially allowing for the re-myelination and restoration of nerve communication in MS patients
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Biogen
Company Location: Eastern America
Company Founding Year: 1978
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Multiple Sclerosis
Phase 1: Multiple Sclerosis|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02228707 |
231HV102 | P1 |
Completed |
Healthy Volunteers |
2016-05-01 |
2019-03-20 |
Treatments |
|
NCT02521545 |
231HV103 | P1 |
Completed |
Multiple Sclerosis |
2015-08-01 |
2019-03-20 |
||
NCT02071121 |
231HV101 | P1 |
Completed |
Healthy Volunteers |
2014-09-01 |
2019-03-20 |
||
NCT04079088 |
231MS201 | P2 |
Withdrawn |
Multiple Sclerosis |
2024-09-18 |
2023-06-02 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|